Biomarker study of immunological response in Japanese patients with stage III non-small cell lung cancer receiving chemoradiotherapy followed by durvalumab
Not Applicable
Recruiting
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000039167
- Lead Sponsor
- Wakayama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Not provided
Exclusion Criteria
1) previously treated with PD-1/PD-L1 inhibitors or anti CTLA-4 antibody
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1) Association between survival and immunological factors in PBMC 2) Association between toxicities and immunological factors in PBMC 3) Association between the efficacy of durvalumab and immunological factors in PBMC 4) Association between the efficacy of durvalumab and proteome analysis
- Secondary Outcome Measures
Name Time Method